Table 1 Compilation of EC 50 and fold change values for site-directed mutants of HIV-2 ROD9 and HIV-1 NL4-3 integrase
From: In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
HIV Type | Strain | EC 50 for DTG (nM) a | n b | Fold Change c |
|---|---|---|---|---|
HIV-2 | Wild-type | 2.3 ± 0.7 | 24 |  |
|  | E92Q | 7.7 ± 1.2 | 3 | 3 |
|  | T97A | 3.2 ± 0.8 | 3 | 1 |
|  | G140S | 3.2 ± 0.8 | 3 | 1 |
|  | Y143C | 7.7 ± 2.2 | 3 | 3 |
|  | Q148H | 3.5 ± 1.4 | 4 | 1 |
|  | Q148K | 23 ± 10 | 4 | 10 |
|  | Q148R | 5.7 ± 2.1 | 4 | 2 |
|  | N155H | 5.0 ± 2.4 | 3 | 2 |
|  | E92Q + Y143C | 15 ± 10 | 5 | 6 |
|  | T97A + Y143C | >10000 | 13 | >5000 |
|  | G140S + Q148R | 108 ± 54 | 7 | 46 |
|  | E92Q + N155H | 25 ± 17 | 7 | 10 |
|  | T97A + N155H | 27 ± 13 | 3 | 12 |
HIV-1 | Wild-type | 1.5 ± 0.6 | 14 |  |
|  | T97A + Y143C | 1.5 ± 0.4 | 4 | 1 |
|  | G140S + Q148R | 6.8 ± 2.7 | 4 | 4 |
|  | E92Q + N155H | 3.6 ± 0.7 | 4 | 2 |